Key facts
- Novo Nordisk said third-quarter adjusted operating profit came in above expectations.
- The company raised its full-year outlook for both profit and sales.
- Novo Nordisk is the maker of the Wegovy weight-loss drug.
- The report did not state the size of the profit beat or the new guidance figures.
Novo Nordisk reported third-quarter adjusted operating profit above expectations on November 4 and raised its full-year profit and sales outlook, the company said in a statement carried by Reuters.
The Wegovy maker did not disclose the profit figure, the size of the beat against analyst estimates, or the new full-year guidance ranges in the report. No basis for the adjusted operating profit, such as currency effects, was given.